SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR

1 .- 47 . (canceled)

48 . A method of treating a disease or a condition, comprising administering to a subject in need thereof an effective amount of a compound of the Formula (A):

or a pharmaceutically acceptable salt thereof, wherein:

X is C or N;

Y is O or S;

R 1 is H, OH, J, OJ, SJ, or NJJ′, wherein J or J′ are each independently a one to ten carbon linear, branched, non-aromatic cyclic, or aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, R, OH, OR, F, Cl, Br, I, NH 2 , NHR, NR 2 , CN, SH, SR, SO 3 H, SO 3 R, SO 2 R, OSO 3 R, and NO 2 , and wherein R is a linear, or branched saturated and unsubstituted C 1 -C 10 alkyl;

R 2 is H or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, R, OH, OR, F, Cl, Br, I, NH 2 , NHR, NR 2 , CN, SH, SR, SO 3 H, SO 3 R, SO 2 R, OSO 3 R, and NO 2 , and wherein R is a linear, or branched saturated and unsubstituted C 1 -C 10 alkyl;

R 3 is H, OH, OG, SG, NGG′ or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein G and G′ are each independently a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group and wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , CN, SH, SO 3 H, and NO 2 ;

R 4 and R 6 are each independently H or a one to ten carbon linear, branched, aromatic cyclic, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, OR, R, F, Cl, Br, I, NH 2 , NHR, NR 2 , CN, SH, SR, SO 3 H, SO 3 R, SO 2 R, OSO 3 R, and NO 2 , and wherein R is a linear, or branched saturated and unsubstituted C 1 -C 10 alkyl;

R 5 is H or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , SO 3 H, and NO 2 ;

is a single bond or a double bond;

wherein the disease or a condition is prostate cancer, breast cancer, ovarian cancer, endometrial cancer, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty or age-related macular degeneration.

49 . The method of claim 48 , wherein the compound has a structure of Formula (B):

or a pharmaceutically salt thereof, wherein:

X is C or N;

Y is O or S;

R 1 is H, OH, J, OJ, SJ, or NJJ′, wherein J or J′ are each independently a one to ten carbon linear, branched, non-aromatic cyclic, or aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , CN, SH, SO 3 H, and NO 2 ;

R 2 is H or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, R, OH, OR, F, Cl, Br, I, NH 2 , NHR, NR 2 , CN, SH, SR, SO 3 H, SO 3 R, SO 2 R, OSO 3 R, and NO 2 , and wherein R is a linear, or branched saturated and unsubstituted C 1 -C 10 alkyl;

R 3 is H, OH, OG, SG, NGG′ or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein G and G′ are each independently a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated alkyl group and wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , CN, SH, SO 3 H, and NO 2 ; and

R 4 is H or a one to ten carbon linear, branched, aromatic cyclic, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, OR, R, F, Cl, Br, I, NH 2 , NHR, NR 2 , CN, SH, SR, SO 3 H, SO 3 R, SO 2 R, OSO 3 R, and NO 2 ,and wherein R is an unsubstituted C 1 -C 10 alkyl;

R 5 is H or a one to ten carbon linear, branched, or non-aromatic cyclic, saturated or unsaturated, optionally substituted alkyl group, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , SO 3 H, and NO 2 ;

Z is an optionally substituted butyl, propyl, ethyl, or methyl, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , SO 3 H, and NO 2 ; and

is a single bond or a double bond.

50 . The method of claim 49 , wherein is a double bond.

51 . The method of claim 48 , wherein the compound has a structure of Formula (C):

or a pharmaceutically acceptable salt thereof, wherein:

A is butyl, propyl, ethyl, or methyl;

M is H, OH, OBu, OPr, OEt, OMe, butyl, propyl, ethyl, or methyl;

T is

E is butyl, propyl, ethyl, or methyl;

Q is

L is butyl, propyl, ethyl, or methyl;

R 8 is Cl 3 C, Cl 2 HC, ClH 2 C butyl, propyl, ethyl, or methyl; and

R 9 is Cl 3 C, Cl 2 HC, ClH 2 C, butyl, propyl, ethyl, or methyl;

and wherein,

A, T, E, Q, and L are optionally substituted, wherein the optional substituent is selected from one or more of: oxo, COOH, OH, F, Cl, Br, I, NH 2 , SO 3 H, and NO 2 .

52 . The method of claim 48 , wherein the compound has a structure of Formula (D):

or a pharmaceutically acceptable salt thereof, wherein:

A is butyl, propyl, ethyl, or methyl;

D is butyl, propyl, ethyl, or methyl;

E is butyl, propyl, ethyl, or methyl;

L is butyl, propyl, ethyl, or methyl;

R 8 is Cl 3 C, Cl 2 HC, ClH 2 C, butyl, propyl, ethyl, or methyl; and

R 9 is Cl 3 C, Cl 2 HC, ClH 2 C, butyl, propyl, ethyl, or methyl.

53 . The method of claim 48 , wherein the compound has a structure of Formula (E):

or a pharmaceutically acceptable salt thereof, wherein:

R 8 is Cl 3 C, Cl 2 HC, ClH 2 C, ethyl, or methyl; and

R 9 is Cl 3 C, Cl 2 HC, ClH 2 C, ethyl, or methyl.

54 . The method of claim 48 , wherein the compound has one of the following structures:

or a pharmaceutically acceptable salt thereof.

55 . The method of claim 48 , wherein the subject is a human.

56 . The method of claim 48 , wherein the condition or the disease is prostate cancer.

57 . The method of claim 56 , wherein the prostate cancer is castration resistance prostate cancer.

58 . The method of claim 56 , wherein the prostate cancer is androgen-independent prostate cancer.

59 . The method of claim 56 , wherein the prostate cancer androgen-dependent prostate cancer.